Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin in Type 2 Diabetes Patients in Routine Internal Medicine and Endocrinology Outpatient Clinical Care; a Retrospective Cohort Study From Turkey

NCT03407196 is registered in ClinicalTrials.gov with AstraZeneca Turkey as lead sponsor.

NCT NCT03407196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03407196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin in Type 2 Diabetes Patients in Routine Internal Medicine and Endocrinology Outpatient Clinical Care; a Retrospective Cohort Study From Turkey
Lead sponsor
AstraZeneca Turkey
Phase
Observational
Overall status
Completed
Start date
May 24, 2017
Completion date
February 28, 2018
Enrollment
1,683 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus